BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc. – Touriquent devices, also known as compressing devices, control or obstruct the arterial and venous blood flow at certain extremities for a specific period of time.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Serum separation gel enables the stable and reliable separation of the blood clot and serum with low influence on the clinical results.

The mounting cases of people suffering from respiratory disorders is the foremost factor driving the global respiratory diagnostics market.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Remote healthcare is a telemedicine service that uses a mobile device to constantly monitor a patient’s condition and performance outside a medical facility.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global platelet-rich plasma market is expected to surpass an impressive valuation of around US $ 1.5 Billion surpassing a CAGR of 12% during the assessment period.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global diabetic neuropathy market is expected to witness a CAGR of 5.9% during the forecast period

Point-of-care or point-of-use diagnostics, sometimes known as bedside testing, has gained increased prominence in analytical testing over the past few years.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Products in the global neonatal monitoring equipment market have been witnessed to receive increasing interest in various nations, especially among the middle income economies owing to high birth rates as well as preference of regional population for efficient and advanced neonatal care.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Advances in optical technologies continue to enrich biomedical research.

Captor Therapeutics S.A. announces that it has selected CPT-6281 as drug candidate for the CT-01 project, which will initially focus on the clinical development of the asset as a TPD treatment against hepatocellular carcinoma.